Completed PHASE1 INTERVENTIONAL 1-arm NCT04322292

A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Conditions Multiple Myeloma

Interventions C-CAR088

Updated 8 times since 2020 Last updated: Feb 9, 2026 Started: Sep 12, 2019 Primary completion: Sep 22, 2022 Completion: Sep 22, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Multiple Myeloma and is currently completed. Institute of Hematology & Blood Diseases Hospital, China leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1

Status: Unknown → Completed
Sep 2025 — Feb 2026 [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

▶ Show 3 earlier versions

Apr 2022 — Oct 2023 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE1
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE1

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Hematology & Blood Diseases Hospital, China

Data source: Institute of Hematology & Blood Diseases Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China